Nav: Home

Forging new defenses against diabetic kidney disease

April 24, 2017

BOSTON - (April 24, 2017) - More than 660,000 people in the United States suffer from end-stage kidney disease, which can only be treated by dialysis or kidney transplantation. Almost half of these patients develop the condition as a complication of diabetes. Scientists at Joslin Diabetes Center now have revealed an unexpected route to slow the progression of diabetic kidney disease, targeting a biological pathway that is the main channel for the metabolism of glucose in the cell.

The finding builds on an earlier surprise from the Joslin Medalist Study program, which looks for clues on how some people live with type 1 diabetes for more than 50 years with unusually low levels of complications, says George King, M.D., Joslin's Chief Scientific Officer and Professor of Medicine at Harvard Medical School. That previous work documented that among Medalists with similar control of their blood glucose levels, some people developed kidney disease and others did not.

Described in a paper in Nature Medicine, the current study set out to find what biological mechanisms might protect the kidneys of healthy Medalists against damage from high blood glucose levels.

Using postmortem kidneys donated from generous Medalists, the Joslin team looked at the levels of thousands of proteins expressed in kidney cells that help to filter blood, and compared the results for Medalists with and without kidney disease.

The investigators expected to observe that the unhealthy kidneys demonstrate high levels of a host of enzymes that process blood glucose, says King, who is corresponding author on the paper. Increased glucose processing has long been thought to inflict damage on the mitochondria (the cell's power generators), which then produce large amounts of reactive oxygen molecules, which in turn leads to kidney disease.

But the Joslin team found just the opposite--much higher levels of these enzymes were detected instead in the protected kidneys.

The scientists got another surprise when they followed up on this finding with mouse experiments that exposed specialized kidney cells called "podocytes", a key component of the blood filtering, to high levels of glucose. "Rather than having damaged mitochondria, somehow these cells, when their glucose metabolism is activated, stimulate themselves to make new mitochondria, so the mitochondria actually work better," King says.

Next, the research team decided to test potential protective treatments by activating a key enzyme in glucose-processing pathways. They picked an enzyme known as PKM2, whose levels almost tripled in healthy Medalists' kidneys compared to diseased kidneys in the study, and which helps the cell take the final step in supplying fuel by the mitochondria. Another reason to pick PKM2 was that cancer researchers have studied the enzyme intensively (because low activity of PKM2 can boost tumor growth) and created many research tools and drug compounds to probe its actions, King says.

After colleagues at Sanofi provided an investigational compound that activates PKM2, the team showed that this compound could stop abnormalities in mouse podocytes both in cell culture and in two mouse models of diabetes.

The experimenters successfully tested the compound in the two mouse models "either treating right at the beginning of diabetes, or for reversal of toxic effects after three or four months of diabetes, which is even more difficult," King says.

Analysis of a small number of kidneys from non-Medalists suggests that similar glucose-processing protective mechanisms may be found in some people with type 2 diabetes as well as type 1 diabetes. Joslin scientists plan to explore kidney disease across a much broader sample of people with diabetes to see if the mechanisms do indeed work across this spectrum, King says.

"Anything we could do to delay the progression of diabetic kidney disease would be very helpful, because the need is great and there hasn't been a new drug in decades," he adds. "This approach also may prove help defend against eye, nerve or other complications of diabetes."
-end-
Joslin's Weier Qi was lead author on the Nature Medicine paper. Other Joslin co-authors included Hillary Keenan, Qian Li, Atsushi Ishikado, I-Hsien Wu, Alison Burkart, Stephanie Hastings, David Pober, Christopher Cahill, Monika Niewczas, Liane Tinsley, Peter Amenta, Edward Feener and Robert Stanton. Other contributors included Aimo Kannt, Thorsten Sadowski and Anja Pfenninger of Sanofi in Frankfurt, Germany; Mark Yorek and Lawrence Coppey of the Veterans Affairs Medical Center in Iowa City, Iowa; Samuel Lockhart of Queen's University Belfast in Belfast, UK; Chong Wee Liew and Guifen Qiang of the University of Illinois at Chicago in Chicago, Illinois; William Israelsen of the University of Texas Southwestern Medical Center in Dallas, Texas; Isaac Stillman of Beth Israel Deaconess Medical Center in Boston; and Matthew Vander Heiden of Massachusetts Institute of Technology in Cambridge, MA.

Lead funding for the work came from the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health (grants 1DP3DK112192-01, DK094333-01 and 1R24DK090961-010); the JDRF; and the Mary Iacocca Research Foundation. Additional research support was provided by Sanofi; the Thomas Beatson, Jr. Foundation; and the Brehm Foundation.

Sanjoy Dutta, JDRF Assistant Vice President, Translational Development & International Partnerships, commented, "JDRF is proud to have supported this research that will ultimately improve the lives of people with type 1 diabetes (T1D) by preventing or delaying progression of kidney disease - one of the highest causes of morbidity and mortality globally. Realizing the importance of taking lessons from human biology, JDRF supported the Joslin Medalist Program that studies individuals with long standing T1D to better understand the progression of diabetes and accelerate development of innovative therapies to thwart the complications associated with diabetes, without the necessity of extreme measures like dialysis or a kidney transplant. We're thankful to the research team for helping to advance JDRF's mission to cure, prevent and treat T1D and its complications."

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.

For more information, visit http://www.joslin.org or follow @joslindiabetes

Joslin Diabetes Center

Related Diabetes Articles:

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
The Lancet Diabetes & Endocrinology: Older Americans with diabetes living longer without disability, US study shows
Older Americans with diabetes born in the 1940s are living longer and with less disability performing day to day tasks than those born 10 years earlier, according to new research published in The Lancet Diabetes & Endocrinology journal.
Reverse your diabetes -- and you can stay diabetes-free long-term
A new study from Newcastle University, UK, has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.
More Diabetes News and Diabetes Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.